ITGAM and glioblastoma: Nigam et al. evaluated a 89Zr-labeled, DFO-chelated anti-CD11b antibody for immuno-PET to noninvasively assess TAMCs in a syngeneic orthotopic glioblastoma model.40 PET imaging and biodistribution revealed high tracer accumulation in the tumor-bearing hemisphere and spleen, correlating with elevated CD11b-positive cell infiltration.